Premium Nahrungsergänzungsmittel | artgerecht

YKL-40 – Biomarker for Inflammation and Cancer

YKL-40 is a glycoprotein used as a biomarker for inflammation, tissue remodeling, and various diseases including cancer, asthma, and neurological conditions.

Regular tips about health Regular tips about health

Things worth knowing about "YKL40"

YKL-40 is a glycoprotein used as a biomarker for inflammation, tissue remodeling, and various diseases including cancer, asthma, and neurological conditions.

What is YKL-40?

YKL-40, also known as Chitinase-3-like Protein 1 (CHI3L1), is a secreted glycoprotein belonging to the family of chitinase-like proteins. The name is derived from the three amino acids at the N-terminus of the protein — Tyrosine (Y), Lysine (K), and Leucine (L) — combined with its molecular weight of 40 kilodaltons. Although YKL-40 shares structural similarities with chitinases, it does not possess enzymatic chitin-cleaving activity.

The protein is produced by various cell types, including macrophages, neutrophils, chondrocytes, synovial fibroblasts, and tumor cells. It plays an important role in inflammatory processes, tissue remodeling, and cell proliferation.

Biological Function

YKL-40 fulfills several functions in the human body:

Inflammation modulation: YKL-40 influences inflammatory signaling pathways and can exert both pro- and anti-inflammatory effects depending on the tissue context.
Tissue remodeling and fibrosis: The protein promotes restructuring of the extracellular matrix and is involved in fibrotic processes in the liver, lungs, and other organs.
Cell growth and survival: YKL-40 stimulates cell proliferation and migration and can promote the survival of tumor cells.
Angiogenesis: The protein supports the formation of new blood vessels, which is particularly relevant in cancer biology.

YKL-40 as a Biomarker

Elevated YKL-40 levels in blood serum or cerebrospinal fluid (CSF) are associated with a wide range of diseases and serve as a diagnostic or prognostic biomarker:

Oncology (Cancer)

Elevated serum YKL-40 levels have been detected in various cancers, including glioblastoma, breast, lung, colorectal, and ovarian cancer. Higher levels frequently correlate with poorer prognosis and shorter survival. YKL-40 is therefore being investigated as a monitoring and prognostic biomarker in oncology.

Respiratory Diseases

In asthma and chronic obstructive pulmonary disease (COPD), YKL-40 levels are elevated and reflect the severity of the disease as well as inflammatory remodeling processes in the airways. In asthma, YKL-40 is associated with a Th2-independent inflammatory phenotype.

Neurological Diseases

Elevated YKL-40 levels have been measured in the CSF and serum of patients with multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. It is considered a marker of neuroinflammatory and neurodegenerative processes, as well as of astrocyte and microglia activation.

Liver Diseases

YKL-40 correlates with the extent of liver fibrosis and cirrhosis and is used for non-invasive assessment of fibrosis severity in chronic liver diseases such as hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD).

Rheumatic Diseases

In rheumatoid arthritis and other inflammatory rheumatic conditions, YKL-40 levels are elevated and correlate with disease activity.

Measurement and Diagnostics

YKL-40 is typically measured using an ELISA (Enzyme-Linked Immunosorbent Assay) in serum, plasma, or CSF. Reference values can vary depending on the laboratory, age, and sex. YKL-40 levels naturally increase with age, so age-corrected reference ranges should be applied during interpretation.

YKL-40 is not a disease-specific biomarker, meaning elevated values must always be interpreted in the clinical context and in combination with further diagnostic investigations.

Clinical Relevance and Future Perspectives

Research into YKL-40 is an active area of medical science. YKL-40 is also being discussed as a potential therapeutic target — particularly in oncology and inflammatory lung diseases, where inhibition of the protein may positively influence the course of disease. Relevant clinical trials are currently underway.

References

Johansen JS. - Studies on serum YKL-40 as a biomarker in patients with rheumatological and liver diseases. - Danish Medical Bulletin, 2006.
Kastrup J, Johansen JS, Winkel P et al. - High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. - European Heart Journal, 2009.
Craig-Schapiro R, Perrin RJ, Roe CM et al. - YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. - Biological Psychiatry, 2010.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category